Search results
Showing 1 to 15 of 17 results for ruxolitinib
Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.
Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]
In development [GID-TA10893] Expected publication date: TBC
NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal.
Show all sections
Sections for TA839
NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal.
Show all sections
Sections for TA840
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Evidence-based recommendations on momelotinib (Omjjara) for treating myelofibrosis-related splenomegaly or symptoms in adults.
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)
Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.
In development [GID-TA11512] Expected publication date: 16 April 2025
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
Technology appraisal and highly specialised technologies appeals
Technology appraisal and Highly specialised technologies appeals
We are listening to your views on this Technology appraisal guidance. Comments close 10 January 2025.
Awaiting development [GID-TA11494] Expected publication date: TBC
In development [GID-TA11007] Expected publication date: TBC
Discontinued [GID-TA10133]
Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)
This guidance has been updated and replaced by NICE technology appraisal guidance TA921.